Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
With
Lakefront Biotherapeutics NV
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Is diagnosed with active noninfectious intermediate-, posterior-, or pan-uveitis
Must have active uveitic disease at the Day 1/Baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite 2 weeks of maintenance therapy with oral prednisone (≥ 10 mg/day to ≤ 60 mg/day) or an oral corticosteroid equivalent:
* ≥ 2+ anterior chamber cells per the Standardization of Uveitis Nomenclature (SUN) criteria
* ≥ 2+ vitreous haze per the National Eye Institute/Standardization of Uveitis Nomenclature (NEI/SUN) criteria
No evidence of active tuberculosis (TB) or untreated latent TB
You may not be if
Participants with elevated intraocular pressures and/or severe glaucoma
Confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV)
Clareo Health | Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
